Compare · GILD vs VCKA
GILD vs VCKA
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Vickers Vantage Corp. I (VCKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and VCKA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $207.86B.
- GILD has hit the wire 20 times in the past 4 weeks while VCKA has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for VCKA).
- Company
- Gilead Sciences Inc.
- Vickers Vantage Corp. I
- Price
- -
- -
- Market cap
- $207.86B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 20
- 0
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Vickers Vantage Corp. I
Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore.
Latest GILD
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
- Director Kramer Kelly A. exercised 10,376 shares at a strike of $66.92 and sold $1,761,437 worth of shares (10,376 units at $169.76) as part of a pre-agreed trading plan (SEC Form 4)
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M sold $557,810 worth of shares (3,399 units at $164.11) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 5,360 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Chairman & CEO O'Day Daniel Patrick exercised 112,429 shares at a strike of $72.34 and sold $19,693,439 worth of shares (112,429 units at $175.16) as part of a pre-agreed trading plan (SEC Form 4)
- New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
- SEC Form 13F-HR filed by Gilead Sciences Inc.
- Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Latest VCKA
- SEC Form 8-K filed by Vickers Vantage Corp. I
- SEC Form SC 13D/A filed by Vickers Vantage Corp. I (Amendment)
- SEC Form EFFECT filed by Vickers Vantage Corp. I
- SEC Form 424B5 filed by Vickers Vantage Corp. I
- SEC Form S-3/A filed by Vickers Vantage Corp. I (Amendment)
- Vickers Vantage Corp. I filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I
- SEC Form 424B3 filed by Vickers Vantage Corp. I